Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support.

cancer caregiver long-term survivors patients testicular

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2019
Historique:
received: 26 02 2019
accepted: 01 05 2019
entrez: 14 6 2019
pubmed: 14 6 2019
medline: 14 6 2019
Statut: epublish

Résumé

Testicular cancer is the most common tumor in young males aged 15-40 years. The overall cure rate for men with testicular cancer is >90%, so a huge number of these patients will become testicular cancer survivors. These people may feel some stress in the experience of diagnosis, treatment, and consequences that affects the quality of life, and during follow-up, especially when new issues and emotional distresses appear over time, such as late side-effects of treatments and emotional challenges including fear of tumor relapse, fertility and sexuality concerns, and social and workplace issues. The cancer experience has an impact not only on patients, but also on their relatives (e.g., spouses, parents, or siblings), who often have to assume a caregiving role for the duration of and following treatment for cancer. Moreover, the caregiver plays an important role in supporting a man with a testicular cancer, providing physical and emotional care. This review presents a summary of existing knowledge regarding the impact and the burden of testicular cancer on caregivers.

Identifiants

pubmed: 31191451
doi: 10.3389/fendo.2019.00318
pmc: PMC6546807
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

318

Références

Psychooncology. 2000 May-Jun;9(3):232-42
pubmed: 10871719
Psychooncology. 2000 Jul-Aug;9(4):303-13
pubmed: 10960928
Psychooncology. 2000 Sep-Oct;9(5):385-94
pubmed: 11038476
J Clin Oncol. 2003 Apr 15;21(8):1513-23
pubmed: 12697875
Eur J Cancer. 2003 Jul;39(11):1517-24
pubmed: 12855257
Bone Marrow Transplant. 2003 Sep;32(5):489-94
pubmed: 12942095
JAMA. 2004 Jan 28;291(4):483-91
pubmed: 14747506
CMAJ. 2004 Jun 8;170(12):1795-801
pubmed: 15184333
Eur J Cancer. 2004 Jul;40(11):1696-703
pubmed: 15251159
Ann Oncol. 2005 Jan;16(1):146-51
pubmed: 15598952
Oncol Nurs Forum. 2005 Mar 05;32(2):273-9
pubmed: 15759065
J Cancer Educ. 2005 Spring;20(1 Suppl):12-6
pubmed: 15916514
Oncol Nurs Forum. 2005 Jul 01;32(4):743-50
pubmed: 15990903
Br J Cancer. 2005 Aug 22;93(4):412-7
pubmed: 16106248
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
Support Care Cancer. 2006 Mar;14(3):251-9
pubmed: 16170559
J Natl Cancer Inst. 2005 Nov 2;97(21):1580-8
pubmed: 16264178
Cancer. 2005 Dec 1;104(11 Suppl):2584-95
pubmed: 16270342
Cancer Nurs. 2006 Mar-Apr;29(2):84-94
pubmed: 16565617
Eur Urol. 2006 Nov;50(5):1032-8; discussion 1038-9
pubmed: 16757095
Support Care Cancer. 2007 Mar;15(3):279-86
pubmed: 16944218
Int J Cancer. 2007 Feb 1;120(3):623-31
pubmed: 17096341
Ann Oncol. 2008 Feb;19(2):259-64
pubmed: 18042838
Am J Mens Health. 2009 Jun;3(2):126-33
pubmed: 19477725
J Clin Oncol. 2009 Dec 10;27(35):5993-9
pubmed: 19858403
Semin Radiat Oncol. 2010 Jan;20(1):67-78
pubmed: 19959033
Psychooncology. 2010 Oct;19(10):1013-25
pubmed: 20014159
J Clin Oncol. 2010 May 1;28(13):2274-9
pubmed: 20368572
Eur Urol. 2010 Jul;58(1):134-40
pubmed: 20395037
J Natl Cancer Inst. 2010 Aug 4;102(15):1114-30
pubmed: 20585105
J Adolesc Health. 2010 Aug;47(2):115-25
pubmed: 20638003
Cancer. 2011 Apr 1;117(7):1331
pubmed: 21425130
J Palliat Med. 2011 Jul;14(7):864-9
pubmed: 21599532
Tumori. 2011 May-Jun;97(3):367-73
pubmed: 21789018
J Clin Oncol. 2012 Apr 10;30(11):1197-205
pubmed: 22412135
BJU Int. 2013 Apr;111(4 Pt B):E207-12
pubmed: 23107372
Cancer. 2013 Jun 1;119 Suppl 11:2160-9
pubmed: 23695928
Health Psychol. 2014 Oct;33(10):1103-12
pubmed: 23957900
Support Care Cancer. 2016 May;24(5):2351-2357
pubmed: 26630950
Cancer. 2016 Apr 1;122(7):1029-37
pubmed: 26848713
Cancer. 2016 Jul 1;122(13):1987-95
pubmed: 26991807
Mol Clin Oncol. 2016 Sep;5(3):258-264
pubmed: 27588190
J Clin Oncol. 2017 Apr 1;35(10):1096-1102
pubmed: 27870561
Cancer. 1989 Oct 1;64(7):1560-7
pubmed: 2789097
Asia Pac J Oncol Nurs. 2015 Jul-Sep;2(3):152-159
pubmed: 27981109
Rev Med Inst Mex Seguro Soc. 2017 Jan-Feb;55(1):25-31
pubmed: 28092244
Oncologist. 2018 May;23(5):617-623
pubmed: 29352051
Psychooncology. 2018 Apr;27(4):1284-1290
pubmed: 29441696
Expert Rev Anticancer Ther. 2018 Apr;18(4):389-397
pubmed: 29516750
J Clin Oncol. 2018 Jul 20;36(21):2160-2168
pubmed: 29874140
Br J Nurs. 2018 Oct 4;27(18):S26-S27
pubmed: 30281354
Crit Rev Oncol Hematol. 2019 May;137:154-164
pubmed: 31014511
Health Psychol. 1993 Jul;12(4):277-85
pubmed: 8404801
J Urol. 1996 Feb;155(2):574-8
pubmed: 8558663

Auteurs

Silvia De Padova (S)

Psycho-Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Chiara Casadei (C)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Alejandra Berardi (A)

Psycho-Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Tatiana Bertelli (T)

Psycho-Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Alessia Filograna (A)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Maria Concetta Cursano (MC)

Medical Oncology Department, Campus Bio-Medico University, Rome, Italy.

Cecilia Menna (C)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Salvatore Luca Burgio (SL)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Amelia Altavilla (A)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Giuseppe Schepisi (G)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Sabrina Prati (S)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Sandra Montalti (S)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Michal Chovanec (M)

Medical Oncology Department, Campus Bio-Medico University, Rome, Italy.
2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia.

Giuseppe Luigi Banna (GL)

Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

Luigi Grassi (L)

University Hospital Psychiatry Unit, Integrated Department of Mental Health and Addictive Behavior, St. Anna University Hospital and NHS Community Health Trusts, Ferrara, Italy.

Michal Mego (M)

Medical Oncology Department, Campus Bio-Medico University, Rome, Italy.
2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia.

Ugo De Giorgi (U)

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

Classifications MeSH